South Africa, a member of the BRICS bloc of leading developing nations including Russia and China, is relying solely on the COVAX syndicate for supply of its vaccines rather than buying directly from producers in both east and west.

South Africa may not receive supplies of COVID-19 vaccines until June despite paying hundreds of millions up front.

The African National Congress (ANC) government’s failure to deliver vaccines in sub-Saharan Africa’s wealthiest yet hardest-hit nation drew criticism from a group of leading doctors and academics on Sunday, including members of the SA Medical Research Council.

The government made a 327 million rand ($22 million) payment to COVAX — an initiative to buy an distribute vaccines to poorer nations, funded by Microsoft founder and world’s richest man Bill Gates — just before Christmas, as a 15 per cent down payment on a 2,18 billion rand ($149 million) fee for supplying vaccines.

But the group argued a wealthy nation like South Africa should not have to rely on COVAX.

“The stunning reality is that it has neither a secured vaccine supply nor a plan for mass inoculation in the foreseeable future that can withstand scrutiny”, the signatories charged. “This portends for this country the worst ravages of Covid-19 in the year ahead.”

And they dismissed claims by officials that early negotiations with producers might have obliged the government to buy ineffective vaccines.

President Cyril Ramaphosa admitted on Tuesday that COVAX would not be able to deliver until the “second quarter” of the year — anywhere between April and June — even while Russia, the UK, the US, Canada and the 27 European Union nations have already begun mass inoculation campaigns with several different vaccines.

On New Year’s Eve, Department of Health Deputy Director Dr Anban Pillay denied the government was putting more lives at risk by not buying currently-available vaccines directly from producers such as Pfizer, Moderna or AstraZeneca — or fellow-BRICS bloc members Russia’s Gamaleya Research Institute or China’s Sinopharm.

Neither Ramaphosa nor Pillay revealed which brands of vaccine COVAX would supply. The South African Health Products Regulatory Authority (SAHPRA) has yet to approve any candidate vaccines against COVID-19 — even those now in widespread use in other countries. But the World Health Organisation (WHO) approved the Pfizer BioNTech vaccine for “emergency” use worldwide on December 31.

While a December press release from SAHPRA stated the organisation was relying on “work done by other regulators”, CEO Dr Boitumelo Semete-Makokotlela indicated it was proceeding slowly out of concern for the “quality, safety and efficacy” of those products.

In a separate Daily Maverick article, columnist Dave Martin urged the government to make use of its membership of the BRICS bloc of leading developing nations to acquire Sinopharm’s Sinovac jab.

South Africa has suffered more from the coronavirus pandemic than any other African nation per head of capita, with almost 29,000 deaths in the last year, despite being one of the wealthiest and developed countries on the continent.

COVAX was set up in 2020 by Gavi, an organisation founded in 1999 with $750 million from Gates through his charitable foundation. Gavi’s funding from the Bill and Melinda Gates Foundation has exceeded £4 billion since then.

Gavi, which “partners” with the WHO, UNICEF and the World Bank, claims to have “helped” vaccinate more than 800 million children in developing nations since 1999.

COVAX Managing Director Aurélia Nguyen worked for British pharmaceutical firm GlaxoSmithKline (GSK) until 2011. GSK and French firm SanofiPasteur are also in the race to develop a coronavirus vaccine, but their formulation is only just entering Phase 2 of clinical trials, according to the WHO.

The stated goal of COVAX is to ensure vaccines are distributed “fairly and equitably” to all 187 countries in the programme, insisting healthcare workers should be prioritised for immunisation before others.

Nguyen told China’s CGTN News that the organisation hoped to distribute 2 billion vaccines this year — far short of the 7.5 billion global population.

She claimed there would be a “very constrained environment in terms of supply.” But the WHO summary shows up to 16 vaccines currently in Phase 3 trials, considered far enough advanced for “emergency” use in the UK, US and EU.

But ANC-allied trade union federation Cosatu condemned the government’s “lethargy” in vaccinating essential workers, the elderly and those with medical conditions that put them at risk from the virus.


Similar articles:

  1. Iran’s COVID vaccine fully home-grown, no Chinese, Cuban role involved: SETAD []
  2. India bars company from exporting vaccines []
  3. India approves AstraZeneca and local COVID vaccines, roll out seen soon []
  4. India approves two Covid-19 vaccines for emergency use []
  5. Covid-19: Which country approved what vaccine? Covid-19: Which country approved what vaccine? []
  6. Bharat Biotech gets permission to manufacture ‘Covaxin’ for sale []
  7. Next step on vaccines []
  8. Covid-19: Egypt approves Sinopharm vaccine for general use []
  9. India’s approval of local vaccine criticised []
  10. India OKs AstraZeneca and locally-made COVID-19 vaccines []
  11. AP Interview: India bars company from exporting vaccines []
  12. India approves AstraZeneca and local COVID vaccines, roll out seen soon []
  13. India’s approval of own COVID vaccine criticised for lack of data []
  14. India Authorizes AstraZeneca and Locally Made COVID-19 Vaccines []
  15. India Clears Two Coronavirus Vaccines for Emergency Use []
  16. Bharat Biotech thanks PM Modi, saying ‘Obliged to contribute to Aatmanirbhar Bharat’ []

Leave a Reply

Your email address will not be published. Required fields are marked *